SGX942 Gets Fast Track Status for Treatment of Oral Mucositis


Get Permission

The FDA has granted fast track designation to the SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in patients with head and neck cancer.

SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability and simultaneous anti-inflammatory and anti-infective activity. The agent has demonstrated safety in a phase I clinical study and efficacy in animal disease models. ■



Advertisement

Advertisement



Advertisement